This is a multipart message in MIME format. ------=_NextPart_000_04EB_01D271B2.06D49C40 Content-Type: multipart/alternative; boundary="----=_NextPart_001_04EC_01D271B2.06D49C40" ------=_NextPart_001_04EC_01D271B2.06D49C40 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Tim =20 Our pleasure to meet with you and your team. Execution, deliverables and = managing client expectations are always of key importance.=20 =20 Polypharmacy is everywhere in over 75 yo cohort but one only sees this = if one is sensitized to look for it as the signs and symptoms are so = common.=20 =20 Looking forward to meeting with you and Mr. Thomas. In the meantime we = will draw up a memo addressing the excellent points raised at our = meeting =20 Jeff =20 =20 From: Timothy Thomas [mailto:tt@homecareassistance.com]=20 Sent: January 18, 2017 12:44 PM To: jeffrey Brock Cc: Maria Licoudis ; Hamsa Assi = ; Janik Fauteux Subject: Re: Follow up =20 Hi Jeff, =20 I wanted to thank you again for stopping by the office with Hamsa. = There's no denying the need for this service. The questions lies in = execution... =20 We're going to review the program as a team once my father returns late = next week. We'll be touch afterwards with next steps.=20 =20 Best regards, Tim. =20 On Tue, Jan 17, 2017 at 1:12 PM, jeffrey Brock > wrote: Maria =20 While it was unfortunate that you could not attend our meeting = yesterday, your obvious understanding of how the issue of polypharmacy = impacts seniors was rather impressive. As you are undoubtedly aware this = condition, affecting anywhere from 40 to 70% of community based seniors = is the number one modifiable risk factor for loss of autonomy, and most = of the time passing under the radar of family physicians and pharmacists = who often lack the knowledge, understanding of this issue and the = clinical information on their clients to address it. =20 =20 I am currently running two polypharmacy pilot projects (one in a CHSLD = and one in an autonomous seniors residence) which consist of three = parts, which has been very successful in stabilizing and in some cases = reversing declining autonomy; =20 1. Risk Assessment =E2=80=93 Done on patient/client metrics, check = listed symptoms & the pharmacy profile 2. Remediation =E2=80=93 Done internally with our medical staff, with a = geriatric pharmacist as required and with the treating physician making = the required changes 3. Follow up =E2=80=93 Ongoing, but for a finite period of time as = medications are slowly and gradually adjusted=20 =20 So often timing is a funny thing, as today I received your excellent = brief on Alzheimer Disease and noticed one crucial missing tidbit of = information. The changes outlined in Stage 2 and 3, so often attributed = to =E2=80=98just aging=E2=80=99 or early dementia may in fact be due to = polypharmacy, as are so many of the other signs and symptoms afflicting = seniors, reducing their autonomy and causing adverse drug reac